Cite
HARVARD Citation
Atkinson, V. et al. (2020). Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. Journal for immunotherapy of cancer. 8 (2), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Atkinson, V. et al. (2020). Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. Journal for immunotherapy of cancer. 8 (2), p. . [Online].